Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease. Impact of a High-Density Lipoprotein-Bound Antioxidant in Secondary Prevention

Journal of the American College of Cardiology

Volumn 54, Issue 14, 2009, Pages 1238-1245

  Regieli, Jakub J ^a   Jukema, J Wouter ^b,c,d   Doevendans, Pieter A ^a   Zwinderman, Aeilko H ^e   Kastelein, John J ^e   Grobbee, Diederick E ^a   van der Graaf, Yolanda ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Durrer Center for Cardiogenetic Research   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

epidemiology; genes; ischemic heart disease; lipoproteins; prognosis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUTAMINE; METHIONINE; PRAVASTATIN;

ADULT; ALLELE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DETOXIFICATION; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; ISOTOPE ANALYSIS; LONG TERM CARE; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CODON; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; GLUTAMINE; HETEROZYGOTE; HUMANS; MALE; METHIONINE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; SMOKING; TRIGLYCERIDES;

EID: 70349182315     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.05.061     Document Type: Article

References (45)

1. Boden W.E., and Pearson T.A. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy (abstr). Am J Cardiol 85 (2000) 645-650
2. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
3. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 97 (1998) 1446-1452
4. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900
5. Parthasarathy S., Barnett J., and Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044 (1990) 275-283
6. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84 (1989) 1086-1095
7. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
8. Palinski W., Rosenfeld M.E., Yla-Herttuala S., et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 86 (1989) 1372-1376
9. Henriksen T., Mahoney E.M., and Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A 78 (1981) 6499-6503
10. Henriksen T., Mahoney E.M., and Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 3 (1983) 149-159
11. Navab M., Imes S.S., Hama S.Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 (1991) 2039-2046
12. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
13. Harel M., Aharoni A., Gaidukov L., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11 (2004) 412-419
14. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
15. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
16. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
17. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
18. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
19. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18 (1998) 1617-1624
20. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
21. van Himbergen T.M., Roest M., de Graaf J., et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 46 (2005) 445-451
22. Roest M., van Himbergen T.M., Barendrecht A.B., Peeters P.H., van der Schouw Y.T., and Voorbij H.A. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 37 (2007) 187-196
23. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
24. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 (1995) 2528-2540
25. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al., Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 338 (1998) 86-93
26. Herings R.M., Bakker A., Stricker B.H., and Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Comm Health (1992) 136-140
27. Cheng S., Pallaud C., Grow M.A., et al. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 36 (1998) 561-566
28. Tregouet D.A., Ricard S., Nicaud V., et al. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler Thromb Vasc Biol 24 (2004) 775-781
29. Grobbee D.E. Future perspectives in atherosclerosis research: an epidemiologic view. In: Koenig W., and Hombach V. (Eds). Progression and Regression of Atherosclerosis (1995), Blackwell Scientific Publications, Vienna 478-482
30. Koerselman J., Van der Graaf Y., de Jaegere P.P., and Grobbee D.E. Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation 107 (2003) 2507-2511
31. Oliver M.F. Prevention of coronary heart disease-propaganda, promises, problems, and prospects. Circulation 73 (1986) 1-9
32. Turban S., Fuentes F., Ferlic L., et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154 (2001) 633-640
33. Chen Q., Reis S.E., Kammerer C.M., et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72 (2003) 13-22
34. Yildiz A., Gur M., Yilmaz R., et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 197 (2008) 257-263
35. Himbergen T.M., van Tits L.J., Voorbij H.A., de Graaf J., Stalenhoef A.F., and Roest M. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med 258 (2005) 442-449
36. Malin R., Laaksonen R., Knuuti J., et al. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11 (2001) 625-633
37. Bergheanu S.C., van Tol A., Dallinga-Thie G.M., et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 23 (2007) 2235-2240
38. Deakin S., Leviev I., Guernier S., and James R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 23 (2003) 2083-2089
39. Tomas M., Senti M., Garcia-Faria F., et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20 (2000) 2113-2119
40. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334 (1996) 1145-1149
41. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., and Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 154-160
42. Jarvik G.P., Tsai N.T., McKinstry L.A., et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22 (2002) 1329-1333
43. Costa L.G., Vitalone A., Cole T.B., and Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69 (2005) 541-550
44. Gouedard C., Barouki R., and Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 24 (2004) 5209-5222
45. Gouedard C., Barouki R., and Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 24 (2004) 2378-2383